<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732406</url>
  </required_header>
  <id_info>
    <org_study_id>2012P001556</org_study_id>
    <nct_id>NCT01732406</nct_id>
  </id_info>
  <brief_title>Acromegaly Treatment Quality of Life Study</brief_title>
  <official_title>Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment of acromegaly will be associated with an
      improvement in quality of life compared to active acromegaly. At the same time, they will
      also be studying the effects of different acromegaly treatments on the quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">134</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Acomegaly with Pegvisomant</arm_group_label>
    <description>Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acromegaly with somatostatin analog</arm_group_label>
    <description>Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Acromegaly</arm_group_label>
    <description>Patients not on drugs for treatment of acromegaly</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There will be 3 groups/cohorts: 1) Patients with active acromegaly (n=30), 2) patients
        receiving pegvisomant monotherapy to treat acromegaly (n=30), and 3) patients receiving
        somatostatin analog monotherapy to treat acromegaly (n=60)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-90

          -  Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin
             analog monotherapy

        Exclusion Criteria:

          -  Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be
             stable for at least 3 months prior to entry into the study

          -  Initiation or discontinuation of testosterone or estrogen within 3 months of entry

          -  Pregnant and nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2012</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Assistant Physician in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 2, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

